Design, synthesis, and pharmacological evaluation of azetedine and pyrrolidine derivatives as dual norepinephrine reuptake inhibitors and 5-HT(1A) partial agonists

Compounds with combined norepinephrine reuptake inhibitor (NRI) and serotonin 1A (5-HT(1A)) partial agonist pharmacology may offer a new therapeutic approach for treating symptoms of neuropsychiatric disorders including ADHD, depression, and anxiety. Herein we describe the design and optimization of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bioorganic & medicinal chemistry letters 2011-01, Vol.21 (2), p.865-868
Hauptverfasser:	Pettersson, Martin, Campbell, Brian M, Dounay, Amy B, Gray, David L, Xie, Longfei, O'Donnell, Christopher J, Stratman, Nancy C, Zoski, Kim, Drummond, Elena, Bora, Gary, Probert, Al, Whisman, Tammy
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenergic Uptake Inhibitors - chemistry Adrenergic Uptake Inhibitors - pharmacokinetics Adrenergic Uptake Inhibitors - pharmacology Animals Anxiety - drug therapy Attention Deficit Disorder with Hyperactivity - drug therapy Azetidines - chemistry Azetidines - pharmacokinetics Azetidines - pharmacology Brain - metabolism Depressive Disorder - drug therapy Dogs Humans Norepinephrine - metabolism Pyrrolidines - chemistry Pyrrolidines - pharmacokinetics Pyrrolidines - pharmacology Receptor, Serotonin, 5-HT1A - metabolism Serotonin 5-HT1 Receptor Agonists - chemistry Serotonin 5-HT1 Receptor Agonists - pharmacokinetics Serotonin 5-HT1 Receptor Agonists - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!